Table 1.
Demographic and clinicopathologic parameters.
| n | % | |
|---|---|---|
| Age, years | ||
| Mean | 53 | |
| Range | 34-73 | |
| Gender | ||
| Male | 17 | 44.7 |
| Female | 21 | 55.3 |
| ECOG performance status | ||
| 0 | 2 | 5.3 |
| 1 | 34 | 89.5 |
| 2 | 2 | 5.3 |
| No. of previous therapies | ||
| 0 | 18 | 47.4 |
| 1 | 15 | 39.5 |
| ≥2 | 5 | 13.2 |
| Radical surgery history | ||
| Yes | 8 | 21.1 |
| No | 30 | 78.9 |
| Histologic type | ||
| Adenocarcinoma | 38 | 100 |
| Non-adenocarcinoma | 0 | 0 |
| Smoking historya | ||
| Never smoker | 30 | 78.9 |
| Smoking index <400 | 1 | 2.6 |
| Smoking index ≥400 | 7 | 18.4 |
| Clinical stage | ||
| IIIB | 4 | 10.5 |
| IV | 34 | 89.5 |
| Gene detection | ||
| ALK | 33 | 86.8 |
| ROS1 | 5 | 13.2 |
| No. of metastatic sites when receiving initial crizotinib therapy | ||
| 0 | 4 | 10.5 |
| 1 | 18 | 47.4 |
| 2 | 13 | 34.2 |
| 3 | 3 | 7.9 |
a Smoking index was calculated as the number of cigarettes smoked per day, multiplied by the number of years of smoking.
Abbreviations used: ECOG: Eastern Cooperative Oncology Group; ALK: anaplastic lymphoma kinase; ROS1: c-ros oncogene 1